Full Title
A Phase 1, Dose Escalation, and Cohort Expansion Study Evaluating NX-5948, a Bruton’s Tyrosine Kinase (BTK) Degrader, in Adults with Relapsed/Refractory B-cell MalignanciesPurpose
Researchers are seeking the best dose of NX-5948 for people with B-cell lymphoma or leukemia that keeps growing after treatment. Examples of these cancers include:
- Chronic lymphocytic leukemia
- Small lymphocytic lymphoma
- Diffuse large B-cell lymphoma
- Follicular lymphoma
- Mantle cell lymphoma
- Marginal zone lymphoma
- Waldenstrom macroglobulinemia
- Primary central nervous system lymphoma
Drugs that block a protein called BTK are used to treat B-cell lymphoma and leukemia. Over time, however, these drugs may stop working. NX-5948 breaks down the BTK protein. It may work well against B-cell lymphomas and leukemias that are no longer responding to drugs that block BTK. NX-5948 is taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have B-cell lymphoma or leukemia that came back or keeps growing after treatment.
- Have recovered from the serious side effects of prior therapies before taking NX-5948.
- Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Meghan Thompson’s office at 646-608-4253.
Protocol
24-178
Disease Status
Relapsed or Refractory
Investigator
Co-Investigators
ClinicalTrials.gov ID
NCT05131022